logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO 2019 — Genetically altered NSCLC tumors are resistant to standard-of-care therapy

STK11 and/or KEAP1 altered tumors present a specialized challenge.